JGP Wealth Management LLC Acquires 719 Shares of Johnson & Johnson $JNJ

JGP Wealth Management LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 1.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 42,165 shares of the company’s stock after acquiring an additional 719 shares during the quarter. JGP Wealth Management LLC’s holdings in Johnson & Johnson were worth $6,441,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GFG Capital LLC acquired a new position in Johnson & Johnson in the second quarter valued at about $35,000. Stone House Investment Management LLC acquired a new position in Johnson & Johnson in the first quarter valued at about $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson in the first quarter valued at about $48,000. von Borstel & Associates Inc. acquired a new position in Johnson & Johnson in the first quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson in the first quarter valued at about $52,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.3%

JNJ opened at $191.79 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market cap of $461.90 billion, a price-to-earnings ratio of 18.51, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The firm has a 50 day simple moving average of $180.09 and a 200 day simple moving average of $164.52. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is 55.61%.

Analyst Ratings Changes

JNJ has been the topic of a number of recent analyst reports. Royal Bank Of Canada restated an “outperform” rating and issued a $209.00 price target on shares of Johnson & Johnson in a research report on Friday, October 10th. Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday. UBS Group upped their target price on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research report on Tuesday. JPMorgan Chase & Co. upped their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Finally, Sanford C. Bernstein upped their target price on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $199.59.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.